Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Ganitumab disappoints in pancreatic cancer: Amgen halts Phase III Study

Written by | 3 Sep 2012

In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).

T-DM1 demonstrates overall survival benefit in metastatic breast cancer: Next target, FDA approval

Written by | 3 Sep 2012

In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab emtansine) offers… read more.

EAHP 2012 Report – Compassionate use and off-label medicines

Written by | 3 Aug 2012

by Zara Qadir reporting on the presentation by Yechiel Hekster (pictured), Professor of Clinical Pharmacy, and a member of The Netherlands Medicines Evaluation Board.

EAHP 2012 Report – Interview with Dr Chantal Bélorgey

Written by | 3 Aug 2012

Zara Qadir interviews Dr Chantal Bélorgey (pictured), Head of Clinical Trial Development at the French national competent authority, Affsaps (Agence française de sécurité sanitaire des produits).

ASCO 2012 Report – Early, highly promising results for Crizotinib (Xalkori) in three aggressive pediatric cancers

Written by | 31 Jul 2012

by Bruce Sylvester – In a phase I study presented at ASCO, researchers reported that crizotinib (Xalkori) stalled tumor growth and, in some cases, eradicated all signs of… read more.

Changes in smoking significantly impacts lung cancer mortality in the U.S. : 1975-2000

Written by | 14 Jun 2012

by Bruce Sylvester – Researchers report that, in the last quarter of the 20th century, changes in smoking behaviors have led to a significant drop in lung cancer… read more.

Children with cancer have complete responses in a Children’s Oncology Group phase 1 trial

Written by | 12 Jun 2012

Pictured: Dr. Yael P. Mosse is a pediatric oncologist at The Children’s Hospital of Philadelphia.  Children’s Hospital of Philadelphia researcher leads trial of ALK inhibitor in neuroblastoma, lymphoma. … read more.

Afatinib slows relapse in NSCLC

Written by | 12 Jun 2012

An investigational oral drug delayed disease relapse for nearly a year in some patients with advanced non-small cell lung cancer (NSCLC).

Respiratory diseases will worsen with global climate change

Written by | 12 Jun 2012

Worldwide increases in the incidences of asthma, allergies, infectious and cardiovascular diseases will result from a variety of impacts of global climate change,

SABCS 2011 Report – Everolimus in management of tumour resistance in breast cancer

Written by | 14 May 2012

by Dr Sunil Upadhyay – The majority of breast cancer patients diagnosed with oestrogen receptor positive tumours respond well to endocrine therapy like tamoxifen and aromatase inhibitors, when… read more.

A review of the EMAS clinical guide: Selective oestrogen receptor modulators for postmenopausal osteoporosis

Written by | 3 May 2012

In  Europe,  osteoporotic  fractures account  for  more  Disability  Adjusted  Life  Years  (DALYs)  lost than common cancers with the exception of lung cancer.

Urgent research needed to determine most effective follow-up care for lung cancer patients

Written by | 23 Apr 2012

Latest study says regular follow-up positive.  Scientist say there is an urgent need for research into all aspects of follow-up care in lung cancer. The study presented in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.